

**Supplementary file 1.**

	Attributed Antibodies
Celiac disease	anti-gliadin, anti-endomysium, tissue transglutaminase antibody IgA and/or IgG
Sjögren's syndrome	anti-Sjögren's-syndrome-related antigen A (SSA); anti-Sjögren's-syndrome-related antigen B (SSB)
Systemic Lupus Erythematosus (SLE)	anti-nuclear antibody (ANA); anti-nucleosome antibody; Anti-cardiolipin; anti-centromere; anti-C1q; anti-b2 glycoprotein; anti-double stranded DNA (ds-DNA)
Autoimmune hepatitis	anti-smooth muscle antibody (SMA); anti-liver kidney microsomal antibodies (LKM-1, LKM-2; LKM-3); anti soluble liver antigen (SLA); liver-pancreas antigen (LP); anti-mitochondrial antibody (AMA); anti-filamentous actin 1 antibody (F1 actin)
Rheumatoid Arthritis (RA)	anti-cyclic citrullinated peptide antibody (CCP); Anti-Rheumatoid Factor (RF) Antibody
Systemic sclerosis (Ssc)	anti-Scl-70 antibody; anti-centromere antibody
Polymyositis/dermatomyositis	anti-Jo-1 antibody
Inflammatory Bowel Disease (IBD)	anti-yeast <i>Saccharomyces cerevisiae</i> (ASCA) anti-neutrophil cytoplasmic antibodies (ANCA)
AI thyroiditis	anti-thyroid peroxidase (TPO), anti-TSH receptor antibodies (TRAb), and anti-thyroglobulin antibodies (Tg)
AI gastritis	anti-parietal cell antibody; anti-intrinsic factor antibody

**Grouping of autoantibodies according to specific autoimmune disorders [1].**

1. Zádori, N., et al., *Prevalence of Autoimmune-phenomena behind Chronic Gastritis of Unknown Origin, and its Role in Poor Histological Outcome of the Stomach: A Single-centre, Retrospective Cross-sectional Study*. Journal of Gastrointestinal and Liver Diseases: JGLD, 2022.

## Supplementary file 2.

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Page No	Recommendation
<b>Title and abstract</b>	1-2	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>		
Background/rationale	2-3	Explain the scientific background and rationale for the investigation being reported
Objectives	2-3	State specific objectives, including any prespecified hypotheses
<b>Methods</b>		
Study design	3-4	Present key elements of study design early in the paper
Setting	4	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	4	(a) Give the eligibility criteria, and the sources and methods of selection of participants
Variables	4	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	4*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	4	Describe any efforts to address potential sources of bias
Study size	4	Explain how the study size was arrived at
Quantitative variables	4	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	4-5	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses
<b>Results</b>		
Participants	5*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	5*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	5*	Report numbers of outcome events or summary measures
Main results	5	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	5	Report other analyses done—eg analyses of subgroups and interactions, and

---

sensitivity analyses

---

**Discussion**

---

Key results	6	Summarise key results with reference to study objectives
Limitations	7	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	7	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	7	Discuss the generalisability (external validity) of the study results

---

**Other information**

---

Funding	8	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	---	---

---

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).